
#Woman_life_freedome #زن_زندگی_آزادی @Toronto, Ontario
Canada
Joined August 2012
- Tweets1.9K
- Following238
- Followers123
- Likes8.5K
Proud to be Iranian-Canadian today. Both my countries are standing firm against Trump’s bullying tactics. Iran, by resisting an unlawful war of aggression, and now Canada, by walking out on his tariff threats. 🇨🇦 #IranianCanadian #Canada #Iran #NoToBullying #SolidarityWithIran
1
391
amiroo retweeted
It must be very liberating for Reza Pahlavi.
Now that everyone knows that he is backed by the country that aims to "bomb Iran back to the stone age," he no longer has to hide his treason.
Makes me think of all the times he and his supporters ferociously denied any relationship with Israel...
It was a great honor to speak alongside Prince @PahlaviReza in a special webinar hosted by the Chaim Herzog Center for Middle East Studies and Diplomacy at @bengurionu with Professor @DanielChamovitz and Minister @GilaGamliel.
This dialogue is another chapter in the ancient friendship between the Persian and Jewish peoples that lives on today.
As Prince Reza Pahlavi so rightly stated, the tyrannical Iranian regime is an existential threat to Israel, the Middle East, Europe, and the entire world. It brutally oppresses its own people, spreads terror around the entire globe, and is the primary obstacle to peace in our region.
Take a look at the video of this special event:
amiroo retweeted
دلیل استیضاح وزیر جنگ امریکا زدن مدرسه میناب اعلام شد اون هم نه یک بار ، سه بار
آقای سلطنت طلب چی شد که به اینجا رسیدی ؟ چی شد که از خودت نپرسیدی پهلوی برای سربازای امریکایی همون روز پیام همدردی فرستاد اما بچه های میناب رو کلا فراموش کرد ؟
amiroo retweeted
میگویند: «وقتی قر میدادیم هنوز نمیدانستیم کودکان میناب را قتل عام کردهاند.» شما مخاطبان پخش زنده نسلکشی خونین غزه بودید. توقع داشتید همان قصابهایی که بیش از ۲۲ هزار کودک فلسطینی را کشتار کردند، روی سر کودک ایرانی گل بریزند؟ هیچ بهانهای از شما شاگردقصابها پذیرفته نیست.
amiroo retweeted
Benjamin Moser explains that Israel is not a democracy: 'It's all theatre; it's actually very oppressive'
amiroo retweeted
With all due respect to the Senator, where was your conviction in June of 2025 when President Trump first violated the Constitution and the 1973 War Powers Act on Iran? Where were you in February of this year when he did it again?
It seems you only found the courage to go in front of a microphone and defend the Constitution after your party won the election, and there’s no more risk to you.
This is why both parties suck.
🚨🇺🇸🇮🇷 Chuck Schumer on Iran:
"We're going to end the Iran war. We have some Republicans already who've joined us in ending the war.
The Founding Fathers had the power of the purse as one of the ways of deterring a president who does war without the consent of the American people."
But what will Trump do between now and January??
Writer: Michael
amiroo retweeted
آیندگان در کتابهای تاریخ خواهند خواند:
آمریکا و اسرائیل دو بار به ایران حمله کردند؛ اما نه یک وجب از خاک ایران را گرفتند و نه با زور توانستند تنگه هرمز را باز کنند.
شکست در میدان جنگ، به شکست سیاسی جنگطلبان در آمریکا و فروپاشی ائتلاف نتانیاهو انجامید.
تاریخ از پسر آخرین شاه ایران نیز خواهد نوشت؛ آنکه در رویای قدرت در رکاب نتانیاهو بر طبل جنگ علیه میهنش کوبید و سرانجام در تاریکی تاریخ گم شد. همچون تحلیلگرانی که در بغض با جمهوری اسلامی، حاضر شدند طرفدار حمله نظامی به ایران شوند.
و از آنان که در داخل ایران، در سایه موساد، با حرفها و مواضع سیاسی به ظاهر سوپر انقلابی، بازیگر نقش مکمل موساد بودند و علیه ایران عمل کردند؛ نامهایی که شاید امروز پنهان باشند، اما فردا در برابر قضاوت تاریخ قرار خواهند گرفت.
ایران تا همیشه میماند، اما جنگ طلبان رفتنی هستند
amiroo retweeted
Last night was a referendum on the Iran war. The American people have emphatically rejected it, and the results at the polls confirmed what we’ve been warning about for months.
President Trump needs to understand that he still has the option to course correct on Iran. End the war now. Walk away, and commit the rest of his term to improving the lives of the American people.
Trump still has the power to do the right thing. He can still avert the disaster of a catastrophic escalation. He needs to focus on taking care of his fellow Americans if he has any hope in salvaging his legacy.
End the war. Put the American people first.
amiroo retweeted
اگر فردا جنگ شد و اینترنت قطع شد، به عنوان یک ایرانی می گم نمی خواهم نه رضا پهلوی، نه ایرانتشال، نه صدا و سیما، نه طرفداران پهلوی، طرفداران جنگ، طرفداران اسرائیل و نه طرفداران آمریکا صدای من در داخل ایران باشند
amiroo retweeted
اگه هنوز براتون سواله چرا ایران آزاد نشده بعد از این همه مبارزه؛ ببینید با کسی مثل ترانه که هر قدم، از جونش، از کارش، از زندگی و سلامتیش هزینه داده چیکار کردیم.
Goldman Sachs reiterates Neutral on $MRNA with a $137 target—38% below its $220.83 close.
Ahead of Nov. 6 earnings, Goldman forecasts $871M revenue vs. $891M consensus and a $1.22/share loss.
Melanoma success is real. But does it justify a valuation pricing in broader oncology success that remains unproven?
1
170
Five warning signs of an emerging AI credit bubble:
SPVs financing massive infrastructure investments. E.g., Blackstone's $63B Project North Star financing for Anthropic's AI infrastructure.
Long-term debt backed by uncertain future revenues. E.g., Anthropic's multiyear compute leases depend on future AI revenues justifying enormous infrastructure costs.
Suppliers using their creditworthiness to finance customers. E.g., Broadcom reportedly guarantees over $42B of senior financing tied to Anthropic's infrastructure.
High borrowing costs before business models prove sustainable. E.g., Project North Star's junior debt reportedly offers yields above 10%, while Anthropic is expected to receive a speculative-grade rating.
Banks transferring credit exposure to other investors. E.g., Blackstone and its banking partners are reportedly seeking buyers for portions of the Anthropic financing.
AI demand may be real, but debt-financed growth introduces a different risk: what happens when cash flows fail to justify the borrowing?
BREAKING: Anthropic is now expected to receive a "high junk" rating from major credit rating agencies after its IPO, which could come as soon as November, per FT.
Details include:
1. Blackstone has told investors that Anthropic likely will not receive an investment-grade rating immediately after its IPO
2. Blackstone is working with banks that stumped up financing on selling the debt on to other investors
3. An investment-grade rating is "central" to Anthropic's ability to continue its AI buildout
4. The company says it expects to spend over $800 billion on computing infrastructure between now and 2045
Debt markets are increasingly in the spotlight as AI funding becomes less abundant.
50
$GOOGL and $AMZN generate billions in profits and cash flow, yet get punished for their spending outlooks.
Meanwhile, cash-burning Moderna $MRNA keeps defying conventional valuation logic.
For now, speculative oncology expectations seem to matter more than fundamentals, cash flow, or realistic forecasts.
171
William Blair downgrades $MRNA to Market Perform after ESMO.
It estimates $5.4B in peak melanoma sales, yet its valuation analysis suggests the stock already prices in a 70–75% probability of success in additional cancers.
The issue isn't melanoma efficacy—it's how much unproven oncology success is priced in.
RBC Capital Markets sees $MRNA's Phase 3 melanoma results near the lower end of expectations and less impressive than earlier-stage data.
The trial succeeded clinically, but did it deliver enough to justify the market's expectations? That's the real question, in my opinion.
Morningstar values $MRNA at $163—even assuming 100% melanoma approval, 60% success in other cancers and $16.8B in risk-adjusted intismeran sales by 2035.
Phase 3 melanoma data are positive. But does that justify ~$80B in market cap? In my opinion, expectations remain excessive.
1
5
317
A powerful gene-editing technique has been used to edit DNA directly in a person’s body — the first known instance of such a treatment.
go.nature.com/4iC2gMn
My bearish $MRNA view following the Phase 3 INTerpath-001 melanoma results presented at ESMO 2026 rests on four concerns:
RFS HR 0.58 confirms efficacy, not commercial success.
NADINA's neoadjuvant immunotherapy offers serious competition for eligible patients.
The incremental contribution of personalized neoantigens versus nonspecific mRNA-LNP stimulation remains unproven.
Overall survival benefit is not yet established; long-term Phase 3 data remain immature.
Clinical success ≠ commercial dominance. In my view, Moderna's valuation still assumes too much. $MRK $BMY
1
3
615













